Home » BOSTON SCIENTIFIC ANNOUNCES START OF CLINICAL TRIAL ASSESSING PRECISION SPINAL CORD NEUROSTIMULATOR
BOSTON SCIENTIFIC ANNOUNCES START OF CLINICAL TRIAL ASSESSING PRECISION SPINAL CORD NEUROSTIMULATOR
Boston Scientific recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) to begin a prospective, randomized, double-blind pivotal trial to evaluate the safety and efficacy of occipital nerve stimulation as a treatment for refractory migraine headache. The study, known as PRISM (PRecision Implantable Stimulator for Migraine), will use Boston Scientific's Precision neurostimulator and involve approximately 150 patients at up to 15 sites in the U.S.
Yahoo News (http://biz.yahoo.com/prnews/051110/neth006.html?.v=33)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May